Shingles Vaccine Market, commonly known as herpes zoster, is a virus that attacks the brain's cranial nerves. It's caused by the varicella zoster virus, which is also responsible for chicken pox. Because the virus can remain dormant in the human body for several years, everyone who has had chicken pox before is at risk of acquiring shingles. According to the Centers for Disease Control and Prevention (CDC), one million cases of shingles were reported in the United States in 2018. Furthermore, the CDC estimates that one out of every three persons in the United States will have shingles at some point in their lives.
Skin rashes, nerve discomfort, eyesight loss, cold, upset stomach, muscle weakness, skin infection, and scarring are some of the symptoms. Antiviral medications such as acyclovir, valacyclovir, and famciclovir are used to treat shingles. These medications aid in reducing the length and intensity of the sickness. Furthermore, analgesics may aid in pain relief.
Merck & Co., Inc. licenced the Zostavax vaccine in 2006, and it is an effective shingles vaccine. The vaccine is indicated for those who are 50 years old or older. The Zostavax vaccination was found to be 64% effective in adults aged 60 to 69 years old in clinical studies. As people get older, their effectiveness decreases, dropping to 41% for those aged 70–79 and 18% for those aged 80 and up. In February 2016, the vaccine was introduced in India at half the price of the US market. In 2015, Zostavax was the sole shingles vaccine on the market, with sales of $749 million.
GlaxoSmithKline (GSK), a global leader in the vaccines business, filed for a U.S. patent in October 2016. The shingles vaccine ‘Shingrix' has received FDA approval. Shingrix has produced better results in clinical trials than Zostavax. In those above the age of 70, the vaccine was 90 percent effective. The vaccine's total efficacy was determined to be 97 percent. Its increased effectiveness, including among the elderly, is expected to promote its global adoption. Shingrix would have a strong competitive position in the global market, which is now monopolised by Zostavax, based on these remarkable trail results. In 201, the corporation is said to have applied for regulatory permissions in Europe and Canada.
The global market for shingles vaccines is seeing an invasion of newer, more expensive medicines. Although the sector is consolidated, new entrants are expected to enter in the near future.
Between 2016 and 2024, North America and Europe are estimated to account for the majority of the market. The market in North America is likely to rise because to rising demand in the United States, while the market in Europe is expected to grow due to increased therapeutic demand from the European Union.
Over the projected period, the Asia Pacific shingles vaccine market is expected to develop at the fastest rate. In the region, particularly in China and India, there is a large potential market that has to be exploited. Companies would benefit from active marketing and differential pricing to strengthen their market position in Asia Pacific.
Shingles is becoming more common over the world, owing to a growing senior population. However, in emerging nations with insufficient insurance coverage, the high expense of vaccines is reducing vaccination. The reduction in postherpetic neuralgia caused by the shingles vaccine is a major source of worry among healthcare professionals. Because of the vaccine's effect in reducing the likelihood of developing herpes zoster, Zostavax has been successful in reducing postherpetic neuralgia to some extent. Shingrix with better results would be a windfall to the lucrative worldwide shingles vaccination market.
Comments
Post a Comment